In recent transactions reported to the Securities and Exchange Commission, Merdad Parsey, the Chief Medical (TASE:) Officer of Gilead Sciences, Inc. (NASDAQ:), a prominent biotech company with a market capitalization of $115 billion, executed significant stock sales. According to InvestingPro data, the stock has shown remarkable strength with a 47% gain over the past six months. On November 27, Parsey sold a total of 163,311 shares of Gilead common stock, amounting to approximately $15.1 million. The shares were sold at prices ranging from $91.7949 to $92.00 per share, near the stock’s 52-week high. InvestingPro analysis suggests the stock is currently fairly valued, with 12 more exclusive insights available to subscribers.
Prior to the sales, Parsey exercised options to acquire 145,413 shares at prices between $57.92 and $65.38, totaling approximately $9.1 million. Following these transactions, Parsey retains direct ownership of 80,801 shares in the company. These transactions were conducted under a pre-established trading plan. For comprehensive analysis of Gilead’s financial health and valuation metrics, access the detailed Pro Research Report available exclusively on InvestingPro.
In other recent news, Gilead Sciences, Inc. has demonstrated significant progress in various clinical trials and financial activities. The company’s investigational HIV prevention drug, lenacapavir, has shown a 96% reduction in HIV infections in a pivotal Phase 3 trial. Additionally, Gilead has issued $3.5 billion in senior notes, intended for general corporate purposes, including repaying existing debt.
RBC Capital Markets and Citi have shown confidence in Gilead, maintaining a Sector Perform rating and assigning a Buy rating respectively. The promising interim results from the Phase 3 ASSURE study on Livdelzi, a treatment for primary biliary cholangitis (PBC), revealed that 81% of PBC patients achieved a composite biochemical response.
Despite the undisclosed specifics of the third quarter 2024 earnings, these recent developments indicate Gilead’s potential for growth and profitability. Furthermore, Citi’s analysis suggests a strong long-term outlook for Gilead, predicting a 5-year revenue and non-GAAP earnings per share (EPS) compound annual growth rate (CAGR) from 2024 to 2029 of 3% and 18%, respectively. These developments emphasize the company’s ongoing commitment to HIV treatment and prevention, as well as its efforts to address the unmet needs of PBC patients.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
